CEACAM5 and non-small cell lung carcinoma: Sawabata et al. reported that pathological I–II NSCLC patients with high preoperative serum CEA (>7.0 ng/mL) exhibited significantly reduced five-year survival rates when compared to patients with normal CEA (five-year survival: high 49% vs. average 72%).